Effect of one or two cycles of dual immunotherapy with nivolumab and ipilimumab in patients with mismatch repair-deficient rectal cancer (RESET-R): interim results from a multicentre, single-arm, phase 2 trial

˜The œLancet. Gastroenterology & hepatology 2026

View at publisher
Authors: Line Schmidt Tarpgaard, L P Poulsen, Ismail Gögenur, Tobias Freyberg Justesen, Søren Rafael Rafaelsen, Nadia Øgaard, Christina Demuth, Camilla Fuchs Andersen, Lise Ventzel, Pernille Øhlenschläger Larsen, Anne Ramlov, Ken Ljungmann
+8 more Michael Bødker Lauritzen, Laura V. Diness, Jakob Lykke, Vinicius Araújo Barbosa de Lima, Søren Kjær, Søren Salomon, Per Vadgaard Andersen, Per Pfeiffer
DOI: 10.1016/s2468-1253(26)00047-6
Cited by: 4
References: 28

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Genetic factors in colorectal cancer Colorectal and Anal Carcinomas

Publication details

Journal / source
˜The œLancet. Gastroenterology & hepatology
Publisher
Elsevier BV
Volume
11
Issue
7
Pages
570–578
Publication date
1 May 2026
Language
EN